Loading…
Actinium Pharmaceuticals, Inc. is projected to rise to $0.8344 by 2027, a +3% move from its current price of $0.8115. ATNM is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.7912 | $0.8118 | $0.8329 | +0.03% |
| Aug 6 | $0.7831 | $0.812 | $0.842 | +0.07% |
| Aug 7 | $0.777 | $0.8123 | $0.8492 | +0.10% |
| Aug 8 | $0.7719 | $0.8126 | $0.8553 | +0.13% |
| Aug 9 | $0.7675 | $0.8128 | $0.8608 | +0.17% |
| Aug 10 | $0.7636 | $0.8131 | $0.8658 | +0.20% |
| Aug 11 | $0.76 | $0.8134 | $0.8705 | +0.23% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.76 | $0.8134 | $0.8705 | +0.23% |
| Week 2 | $0.7407 | $0.8153 | $0.8974 | +0.46% |
| Week 3 | $0.7265 | $0.8171 | $0.9191 | +0.70% |
| Week 4 | $0.7151 | $0.819 | $0.9381 | +0.93% |
| Week 5 | $0.7054 | $0.8209 | $0.9554 | +1.16% |
| Week 6 | $0.6968 | $0.8228 | $0.9716 | +1.40% |
| Week 7 | $0.6892 | $0.8247 | $0.9869 | +1.63% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease.
It also develops ATNM-400, a antibody radioconjugate that deliver alpha-emitter Ac-225 to prostate cancer cells. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia.
Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.
ATNM is the stock = Actinium Pharmaceuticals, Inc. trading at $0.8544 with a market cap of $26.81M and a rank of 4593.
The current price sits in proximity to a 30-day trading range of $0.7051 to $1.04, with the current price at $0.8544 and a market position ranked at 4593.
Forecasts project a long horizon of price evolution, beginning with a 2026 average of $0.8544 and a 2026 max of $1.10, and progressing toward higher averages in later years (2030 avg $0.9007, max $1.33; 2032 avg $1.19, 2033 avg $1.25; 2034 avg $1.34; 2040 avg $1.91; 2050 avg $2.90) with increasing upside (2032 ROI 38.7%, 2040 ROI 124%, 2050 ROI 239.3%).
Sentiment shifts from NEUTRAL in the near term to BULLISH in the later years, reflecting an improving price outlook over the long term, though these are estimates and not guarantees.
A major floor 14.4% below — a decisive break under it would weaken the trend.
Support has flipped 3.1% overhead — reclaiming it would be bullish.
The nearest ceiling, 29.4% above — a clean break opens room to run.
A major ceiling 87.3% above — clearing it would confirm fresh momentum.
Key ATNM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ATNM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.8464 | Sell | $0.8475 | Sell |
| MA 10 | $0.8666 | Sell | $0.8654 | Sell |
| MA 20 | $0.9039 | Sell | $0.8997 | Sell |
| MA 50 | $1.00 | Sell | $0.9849 | Sell |
| MA 100 | $1.09 | Sell | $1.07 | Sell |
| MA 200 | $1.22 | Sell | $1.23 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 34.06 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -112.60 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -9.02 | Sell |
| Bollinger %B (20,2) | 0.18 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.68 | Sell |
| Awesome (5,34) | -0.10 | Sell |
| Ultimate (7,14,28) | 23.56 | Buy |
| Momentum (10) | -0.08 | Sell |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 0.83 | Sell |
| ADX (14) | 24.41 | Sell |
| ATR (14) | 0.02 | Info |
The 30-day technical picture is BEARISH, with RSI14 at 30. The near-term momentum sits below neutral, consistent with a cautious stance.
Key moving averages show SMA50 at $1.04 and SMA200 at $1.23, indicating the stock is trading below or near the shorter-term trend line while still tethered to longer-term levels.
The immediate support is at $0.854 and resistance at $1.05, with a 30-day price range from $0.7051 to $1.04. Annualized volatility stands at 60%, underscoring elevated risk in the short run.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.8115 | $0.8115 | $1.04 | 0% | Neutral | |
| $0.6693 | $0.8344 | $1.10 | +3% | Neutral | |
| $0.6464 | $0.8275 | $1.13 | +2% | Neutral | |
| $0.6571 | $0.8597 | $1.20 | +6% | Neutral | |
| $0.6419 | $0.8559 | $1.23 | +5% | Neutral | |
| $0.7116 | $0.9656 | $1.41 | +19% | Neutral | |
| $0.8042 | $1.11 | $1.65 | +37% | Bullish | |
| $0.8276 | $1.16 | $1.76 | +43% | Bullish | |
| $0.8863 | $1.26 | $1.94 | +55% | Bullish | |
| $0.8308 | $1.20 | $1.87 | +47% | Bullish | |
| $1.16 | $1.77 | $2.94 | +118% | Bullish | |
| $1.60 | $2.73 | $4.93 | +236% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.8115 | $0.8115 | $0.9716 | +0.00% |
| September 2026 | $0.6856 | $0.8092 | $0.9807 | -0.28% |
| October 2026 | $0.704 | $0.8363 | $1.02 | +3.35% |
| November 2026 | $0.7152 | $0.8541 | $1.05 | +2.13% |
| December 2026 | $0.6957 | $0.8348 | $1.04 | -2.26% |
Click any year to see its month-by-month ATNM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, ATNM is projected to trade between $0.8115 and $1.04, averaging $0.8115 — a potential gain of 0% from today's $0.8115. A consolidation phase looks the most probable path here.
Actinium Pharmaceuticals, Inc.'s 2027 outlook centres on $0.8344, within a $0.6693 to $1.10 range. That is up +3% on the projected 2026 average. That marks a +3% change versus current levels. Price action looks broadly range-bound.
By 2028, ATNM could reach as high as $1.13, with a base case around $0.8275 and support toward $0.6464 — roughly +2% from $0.8115. A consolidation phase looks the most probable path here.
Expect ATNM to range from $0.6571 to $1.20 through 2029. The $0.8597 average target implies a +6% move from current prices. That is up +4% on the projected 2028 average. Price action looks broadly range-bound.
The ATNM price prediction for 2030 points to an average of $0.8559 (low $0.6419, high $1.23) — a potential gain of +5% on today's $0.8115. A consolidation phase looks the most probable path here.
In 2031, ATNM is projected to trade between $0.7116 and $1.41, averaging $0.9656 — a potential gain of +19% from today's $0.8115. That is up +13% on the projected 2030 average. Price action looks broadly range-bound.
Actinium Pharmaceuticals, Inc.'s 2032 outlook centres on $1.11, within a $0.8042 to $1.65 range. That is up +15% on the projected 2031 average. That marks a +37% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, ATNM could reach as high as $1.76, with a base case around $1.16 and support toward $0.8276 — roughly +43% from $0.8115. Momentum favours further upside here.
Expect ATNM to range from $0.8863 to $1.94 through 2034. The $1.26 average target implies a +55% move from current prices. That is up +9% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The ATNM price prediction for 2035 points to an average of $1.20 (low $0.8308, high $1.87) — a potential gain of +47% on today's $0.8115. Momentum favours further upside here.
In 2040, ATNM is projected to trade between $1.16 and $2.94, averaging $1.77 — a potential gain of +118% from today's $0.8115. That is up +48% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Actinium Pharmaceuticals, Inc.'s 2050 outlook centres on $2.73, within a $1.60 to $4.93 range. That is up +54% on the projected 2040 average. That marks a +236% change versus current levels. Momentum favours further upside here.
Investing $1,000 in ATNM today (≈ 1,232.28589 ATNM) could be worth
$3,361.7
+$2,361.7 (+236%) by 2050 · US Dollar
Based on the average projected ATNM price of $2.73 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ATNMwould be worth at today's price.
$1,000 invested in ATNM on Jul 31, 2025 (≈ 613.496934 ATNM) would be worth
$497.85
-$502.15 (-50.2%) today · 0.50× · US Dollar
Based on a ATNM entry price of $1.63 vs. today's $0.8115.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.86 | $943.6 | -5.6% |
| 1 month ago | $0.98 | $828.06 | -17.2% |
| 3 months ago | $1.13 | $718.14 | -28.2% |
| 6 months ago | $1.22 | $665.16 | -33.5% |
| 1 year ago | $1.63 | $497.85 | -50.2% |
| All time (5.0y) ago | $6.94 | $116.93 | -88.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ATNM forecast.
Our base-case forecast reaches $1.60 around 2040.
Implied market cap at $1.60: $50.2M
The multi-year forecast shows a path from neutral in 2026 toward stronger upside in later years. The 2030 forecast yields an average of $0.9007 with a max of $1.33 and a 5.4% ROI, followed by 2031 with an average of $1.02 and 19.2% ROI. The momentum accelerates in 2032, with an average of $1.19 and a 38.7% ROI, and continues higher through 2033 ($1.25 avg, 46.3% ROI) and 2034 ($1.34 avg, 57.2% ROI).
By 2040 the forecast shows an average of $1.91 and a 124% ROI, and by 2050 an average of $2.90 with a 239.3% ROI, reaching a max of $5.49. These figures indicate a shift to a bullish outlook in the longer term, though the projections are estimates and not guarantees. Investors should consider the inherent uncertainty and the fact that sentiment changes to bullish only from 2032 onward in the provided horizon.
Tap a question to reveal the answer.
The 2030 forecast shows an average of $0.9007, with a min of $0.6605, a max of $1.33, and a ROI of 5.4%. The sentiment is NEUTRAL.
Forecasts through 2031 are NEUTRAL, with a notable bullish shift beginning in 2032 (avg $1.19, ROI 38.7). From 2040 onward the outlook turns strongly bullish (avg $1.91 in 2040, ROI 124%; avg $2.90 in 2050, ROI 239.3%), though these are estimates and not guarantees.
Yes. The forecast shows a max of $2.14 in 2034 and a max of $5.49 in 2050, indicating possible upside beyond $2 over the longer term.
Bearish sentiment with RSI 14 at 30. The stock trades with SMA50 at $1.04 and SMA200 at $1.23. The 30-day range is $0.7051 to $1.04, with support at $0.854 and resistance at $1.05.
Current price is $0.8544 and market cap is $26.81M, with a rank of 4593.
Actinium Pharmaceuticals, Inc. Community Discussion
0Share your Actinium Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.